A case of COVID-19 pneumonia successfully treated with favipiravir (Avigan) in which serum SARS-CoV-2 RNA detected by LAMP method was clinically useful
Copyright © 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved..
A 49-year-old Japanese male was managed by mechanical ventilation due to coronavirus disease 2019 (COVID-19) pneumonia. Favipiravir as an antiviral therapy, and anti-inflammatory treatment were administered. SARS-CoV-2 RNA was detected in serum by the loop-mediated isothermal amplification (LAMP) method on Day 9; favipiravir treatment was continued. On Day 13, negative serum RNA was confirmed, followed by mechanical ventilation was removed. On Day 23, LAMP negative was confirmed in nasopharynx, after that the patient discharged on Day 27. We could treat successfully for severe COVID-19 pneumonia based on the LAMP method. We consider this method will be useful in COVID-19 treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy - 27(2021), 2 vom: 10. Feb., Seite 379-383 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hirouchi, Takatomo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Amides |
|---|
| Anmerkungen: |
Date Completed 29.01.2021 Date Revised 27.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jiac.2020.10.011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318344483 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318344483 | ||
| 003 | DE-627 | ||
| 005 | 20231225165148.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jiac.2020.10.011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1061.xml |
| 035 | |a (DE-627)NLM318344483 | ||
| 035 | |a (NLM)33268271 | ||
| 035 | |a (PII)S1341-321X(20)30370-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hirouchi, Takatomo |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A case of COVID-19 pneumonia successfully treated with favipiravir (Avigan) in which serum SARS-CoV-2 RNA detected by LAMP method was clinically useful |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.01.2021 | ||
| 500 | |a Date Revised 27.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a A 49-year-old Japanese male was managed by mechanical ventilation due to coronavirus disease 2019 (COVID-19) pneumonia. Favipiravir as an antiviral therapy, and anti-inflammatory treatment were administered. SARS-CoV-2 RNA was detected in serum by the loop-mediated isothermal amplification (LAMP) method on Day 9; favipiravir treatment was continued. On Day 13, negative serum RNA was confirmed, followed by mechanical ventilation was removed. On Day 23, LAMP negative was confirmed in nasopharynx, after that the patient discharged on Day 27. We could treat successfully for severe COVID-19 pneumonia based on the LAMP method. We consider this method will be useful in COVID-19 treatment | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Favipiravir | |
| 650 | 4 | |a Loop-mediated isothermal amplification (LAMP) | |
| 650 | 4 | |a Viremia | |
| 650 | 7 | |a Amides |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Pyrazines |2 NLM | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 650 | 7 | |a favipiravir |2 NLM | |
| 650 | 7 | |a EW5GL2X7E0 |2 NLM | |
| 700 | 1 | |a Ota, Shinichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Mashima, Dai |e verfasserin |4 aut | |
| 700 | 1 | |a Boku, Ryuichi |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshida, Yuto |e verfasserin |4 aut | |
| 700 | 1 | |a Iwata, Koki |e verfasserin |4 aut | |
| 700 | 1 | |a Shinada, Kanako |e verfasserin |4 aut | |
| 700 | 1 | |a Matsumoto, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Morikawa, Miwa |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Shinoda, Masahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Kamachi, Kenichi |e verfasserin |4 aut | |
| 700 | 1 | |a Shinkai, Masaharu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy |d 1996 |g 27(2021), 2 vom: 10. Feb., Seite 379-383 |w (DE-627)NLM095488073 |x 1437-7780 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2021 |g number:2 |g day:10 |g month:02 |g pages:379-383 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jiac.2020.10.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2021 |e 2 |b 10 |c 02 |h 379-383 | ||